Back to top

Analyst Reiterates Buy on Curis, Maintains $17 Price Target Amid Progress in TakeAim CLL Trial and Nasdaq Compliance Steps

Curis, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sara Nik from H.C. Wainwright maintained a Buy rating o...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Curis, Inc. (CRIS)